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Identity 
Other names: ADIP 
HGNC (Hugo): SSX2IP 
Location: 1p22.3 
Note 
SSX2IP gene encodes the protein SSX2IP which 
interacts with the cancer-testis antigen SSX2. It is 
thought that SSX2IP regulates the function of SSX2 in 
the testes and malignant cells. The rodent equivalent is 
known as afadin DIL domain-interacting protein 
(ADIP) and the chicken orthologue is called clock-
controlled gene (LCG) (Breslin et al., 2007). 
DNA/RNA 
Note 
The SSX2IP gene is located on chromosome 1p22.3 
(Entrez Gene). 
Description 
SSX2IP includes over 46 kb and consists of 14 
exons however the first one is not translated (de Bruijn 
et al., 2002). 
Transcription 
The gene contains 33 introns. 18 different mRNAs are 
produced; 17 spliced and 1 un-spliced form (Thierry-
Mieg and Thierry-Mieg, 2006). 
Pseudogene 
A pseudogene of this gene is found on chromosome 3 
(provided by RefSeq, Oct 2009 from Entrez Gene). 
Protein 
Note 
SSX2IP was discovered due to its interaction with 
SSX2 in a yeast two-hybrid system and believed to 
regulate the function of SSX2 in the testes and 
malignant cells (de Bruijn et al., 2002). 
Description 
There are 3-4 coil coiled regions in each version of 
SSX2IP. Only human SSX2IP has a nuclear 
localisation signal (NLS). 
 
 
Location of SSX2IP gene on chromosome 1 and the surrounding region. 
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Structural representation of SSX2IP protein in human, mouse and chicken showing the binding regions (Breslin et al., 2007). 
 
Expression 
Expression observed in various normal tissues, the 
highest being in the brain (de Bruijn et al., 2002). 
It is expressed less but significantly in kidney, testes, 
spinal cord, liver, heart, lung, pancreas, skeletal 
muscle, ovary, placenta, foetal liver and foetal brain 
(Breslin et al., 2007). 
Localisation 
SSX2IP co-localises with SSX2 to the nucleus and 
some fragments to the cytoplasm (de Bruijn et al., 
2002).  
It has also been seen to localise on the surface of 
myeloid cell lines and primary AML (Denniss et al., 
2007).  
ADIP co-localises with afadin at adherens junctions 
and in perinuclear regions (Asada et al., 2003). 
Function 
It has been suggested that SSX2IP regulates the 
function of SSX2 (de Bruijn et al., 2002).  
Rodent ADIP binds with F-actin binding proteins 
afadin and α-actinin and could therefore be involved in 
forming actin structure at cell-cell adherens junction as 
well as construction of actin bundle at nectin-based cell 
adhesion sites (Asada et al., 2003).  
Through its interaction with the actin-binding protein 
β-spectrin, ADIP may have a role in actin-dependent 
organization of the Golgi complex. ADIP binds β'-cop, 
which is a subunit of the coatomer complex, proposing 





Acute myeloid leukaemia 
Note 
SSX2IP expression has been seen to be elevated in 
33% of acute myeloid leukaemia patient samples at 
presentation (Guinn et al., 2005).  
Peak expression on the surface of myeloid leukaemia 
cells is during mitosis (Denniss et al., 2007). Patients 
with the t(15;17) translocation have increased levels of 
SSX2IP whereas expression is decreased in patients 
with the t(8;21) translocation (Guinn et al., 2008). 
Prognosis 
Patients with no chromosomal abnormalities showed 
improved survival rates with elevated expression of 
SSX2IP.  
High level of SSX2IP expression is associated with 
other positive prognostic markers such as days in 
remission and age at diagnosis (Guinn et al., 2009). 
Cytogenetics 
The t(15;17) translocation leads to PML-RARα 
product.  
Overexpression of PML during the cell cycle leads to 
G1 arrest in normal fibroblasts which cannot occur 
once PML attaches to RARα.  
Genes regulating cyclin dependent kinase activity are 
upregulated in correlation with overexpression of 
SSX2IP.  
The t(8;21) translocation generates the AML1-ETO 
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Cells with this gene product develop aneuploidy due to 
decreased regulation at the spindle checkpoint.  
Low levels of SSX2IP relate to reduced expression of 
CDC20, a substrate-targeting subunit of the anaphase-
promoting complex (Guinn et al., 2008). 
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